Developing an effective treatment for sepsis and severe sepsis based upon our aSeptiMab™ therapeutic and commercializing our IVD test for plasma iNOS, are only the first steps for DSX Therapeutics. Our on-going research and development projects continue to produce new and exciting results that can be applied to other underserved clinical markets. Our aim is to transition our novel research findings out of the laboratory and into new clinical products to diagnose more easily and to treat for effectively other inflammatory pathologies.

Future Therapeutic Products

  • Small molecular weight inhibitor of iNOS formation

  • Small molecular weight inhibitor of iNOS function

  • Future Therapeutic Products for other inflammatory conditions

    • Rheumatoid arthritis

    • Inflammatory bowel disease

      • Ulcerative colitis

      • Crohn’s disease

    • Transplant and graft rejection

Future In Vitro Diagnostic tests

  • Clinical laboratory Auto-Analyzer test for sepsis

  • Point-of-Care device for sepsis and severe sepsis

  • Flow cytometry clinical test for sepsis

  • Future In Vitro Diagnostic Test Products for other inflammatory conditions

    • Rheumatoid arthritis

    • Inflammatory bowel disease

      • Ulcerative colitis

      • Crohn’s disease

    • Transplant and graft rejection

Home | News | R&D Vision | Presidentís Message | Achievements | Leadership Team | Technology | Contact